- Johnson Controls International PLC JCI has signed a joint development agreement with Phylagen, a biotechnology company in microbiome optimization of indoor environments.
- The agreement includes a strategic investment in Phylagen. The financial terms of the deal were not disclosed.
- Through this agreement, the companies develop cutting-edge technology that leverages the science of building microbiomes to improve the future of healthy buildings.
- Price Action: JCI shares traded higher by 1.87% at $74.18 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
